Skip to Main Content

Paper Details

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Oncologist
35
2016
Breast Cancer, CYP2D6, Endoxifen, IM, Patients, Polymorphic CYP2D6, Tamoxifen, breast cancer, endoxifen, patient, patients, tamoxifen
Author NameAffiliation
Joseph G IbrahimUniversity of North Carolina at Chapel Hill
Joseph G IbrahimUniversity of North Carolina at Chapel Hill
Karen E WeckUniversity of North Carolina at Chapel Hill
Jeffrey PeppercornDuke University
James P EvansUniversity of North Carolina at Chapel Hill
Howard L McLeodMoffitt Cancer Center
Howard L McLeodMoffitt Cancer Center
Lisa A CareyUniversity of North Carolina at Chapel Hill
  • 1 - 8

Datasets

Release 1.2